from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. The drug dalfampridine.


Sorry, no etymologies found.


  • AMPYRA, which was previously referred to as Fampridine-SR, is an extended release tablet formulation of dalfampridine 4-aminopyridine, 4-AP, which was previously called fampridine, and remains known by that name outside the US.

  • AMPYRA is an extended release tablet formulation of the investigational drug dalfampridine (4-aminopyridine and called fampridine outside the U.S.).

    The Earth Times Online Newspaper

  • He added that Ampyra, which was previously referred to as fampridine-SR, is the only medication indicated for this use.

    PharmaTimes World News

  • The U.S. Food and Drug Administration has approved the marketing of Ampyra ™ (dalfampridine, formerly known as fampridine S., from Acorda Therapeutics) for its ability to improve walking speed in people with any type of multiple sclerosis.


  • Ampyra, formerly known as fampridine SR, is a tablet containing a sustained-release formula of 4-aminopyridine, which blocks tiny pores, or potassium channels, on the surface of nerve fibers.


  • Test Drug Improves Walking Ability in Some Multiple Sclerosis Patients: Research An experimental drug called fampridine improves walking ability in some patients with multiple sclerosis (MS), a disease of the nervous system that crimps mobility, a study published on Frid ...

    Medindia Health News

  • Less than a month after the Food and Drug Administration said there was a problem with its application, Acorda Therapeutics delivered a new drug application for fampridine-sr, its treatment for multiple sclerosis.

    Selloff Stings Conmed and NCR but Spares Acorda

  • AMPYRA should not be taken with other forms of 4-aminopyridine 4-AP, fampridine, since the active ingredient is the same.

  • On July 20, the European Commission granted conditional approval for FAMPYRA ® (prolonged-release fampridine tablets) to improve walking in adult patients with multiple sclerosis (MS) who have walking disabilities (EDSS 4-7).

  • Use has issued a negative opinion recommending against approval of FAMPYRA prolonged-release fampridine 10 mg tablets to improve walking ability in adult patients with multiple sclerosis in the European Union.

    In Play &reg - Yahoo! Finance - The basics of investing.


Log in or sign up to get involved in the conversation. It's quick and easy.